Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy

This publication has 74 references indexed in Scilit:

• Imatinib Plasma Monitoring-Guided Dose Modification for Managing Imatinib-Related Toxicities in Gastrointestinal Stromal Tumor Patients
  Journal of Korean Medical Science, 2013
• Should therapeutic drug monitoring of the unbound fraction of imatinib and its main active metabolite N-desmethyl-imatinib be developed?
  Cancer Chemotherapy and Pharmacology, 2012
• Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial
  Haematologica, 2012
• New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
  European Journal of Cancer, 2009
• Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability
  British Journal of Cancer, 2008
• Pharmacokinetic-Pharmacodynamic Relationships of Imatinib and Its Main Metabolite in Patients with Advanced Gastrointestinal Stromal Tumors
  Clinical Cancer Research, 2006
• Adherence to Medication
  New England Journal of Medicine, 2005
• Clinical Pharmacokinetics of Imatinib
  Clinical Pharmacokinetics, 2005
• Imatinib Mesylate — A New Oral Targeted Therapy
  New England Journal of Medicine, 2002
• Clinical Pharmacodynamics of High-Dose Methotrexate in Acute Lymphocytic Leukemia
  New England Journal of Medicine, 1986